Crohn's Disease
Conditions
Keywords
Crohn's disease, Infliximab, T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3)
Brief summary
This study investigated the expression of T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) in the colonic mucosa and/or the peripheral blood of children with Crohn's disease during anti TNF-α (infliximab) therapy.
Detailed description
The immunoregulatory effects of TIM-3 on patients with Crohn's disease according to the treatment have not yet been investigated.
Interventions
DRUGInfliximab
Sponsors
Samsung Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
13 Years to 17 Years
Healthy volunteers
Yes
Inclusion criteria
* •Pediatric patients who were diagnosed with severe Crohn's disease who require infliximab treatment * confirmed diagnostic of Crohn's disease in clinical, endoscopic and histological findings
Exclusion criteria
* •patients who has proven to have infliximab antibody
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease with anti TNF-α Therapy | 1-year treatment period | Disease Activity Index (PCDAI) scores, Peripheral blood for TIM-3 mRNA expression |
Countries
South Korea
Outcome results
None listed